Back to search results

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Abroad (travel likely)Recruiting

Conditions

Chronic Kidney Disease(CKD) · Type 2 DM · Type 2 Diabetes Mellitus (T2DM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama, Birmingham, Alabama, United States

    Contact: Study coordinator (Sarah Machado) · smachado@uabmc.edu
    Contact: Principal Investigator (Clare Lyas, MD)

  • Orlando Health, St. Petersburg, Florida, United States

    Contact: Principal Investigator (Timothy Marsh, DO)

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Angie Westover) · funke@med.umich.edu · 734-936-6467
    Contact: Principal Investigator (Ilka Decker)

  • Essentia Health, Duluth, Minnesota, United States

    Contact: Study coordinator (Haley Messenger) · haley.messenger@essentiahealth.org
    Contact: Principal Investigator (Sreedhar Devathi, MD)

  • Duke University, Durham, North Carolina, United States

    Contact: Study coordinator (Kim Cicio) · kimberly.cicio@duke.edu
    Contact: Principal Investigator (John Middleton, MD)

  • Houston Methodist, Houston, North Carolina, United States

    Contact: Study coordinator (Daphne Medina)
    Contact: Study coordinator (Steven Puckett) · srpuckitt@houstonmethodist.org
    Contact: Principal Investigator (Peter Nguyen)

  • Baylor Scott & White, Temple, Texas, United States

    Contact: Principal Investigator (Tariq Shafi, MD)
Study leads

  • Neha Pagidipati, MD

    Principal Investigator

    Duke University

View source on ClinicalTrials.gov(opens in a new tab)